Replies to post #62514 on SEASONALITY STOCK REPORTS

[Preciouslife1]

SUNSTAR Wednesday, 10/15/14 09:59:10 AM
Re: None
Post # of 193739
Bavituximab’s broad spectrum targets are cancers, enveloped viruses, like Ebola, and other diseases. It’s bavi’s universal target, PS, that is densely associated with these diseases, that will drive PPHM as the FDA approvals occur.

This broad spectrum universality of bavituximab will drive PPHM market cap growth exponentially from here going forward.

Bavi will be one the the first immunotherapy agents approved by FDA, IMO, allowing Peregrine to move from a small cap pharmaceutical, to directly competing with big pharmas for market share.

Broad spectrum means market leverage.

IMO

sunstar